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A B S T R A C T
Background
Asthma is a chronic inflammatory disease of the airways affecting an estimated 334 million people worldwide. During severe exacerba-
tions, patients may need to attend amedical centre or hospital emergency department for treatment with systemic corticosteroids, which
can be administered intravenously or orally. Some people with asthma are prescribed oral corticosteroids (OCS) for self-administration
(i.e. patient-initiated) or to administer to their child with asthma (i.e. parent-initiated), in the event of an exacerbation. This approach
to treatment is becoming increasingly common.
Objectives
To evaluate the effectiveness and safety of patient- or parent-initiated oral steroids for adults and children with asthma exacerbations.
Search methods
We identified trials from Cochrane Airways’ Specialised Register (CASR) and also conducted a search of the US National Institutes of
Health Ongoing Trials Register ClinicalTrials.gov (www.clinicaltrials.gov) and the World Health Organization International Clinical
Trials Registry Platform (apps.who.int/trialsearch). We searched CASR from its inception to 18 May 2016 and trial registries from
their inception to 24 August 2016; we imposed no restriction on language of publication.
Selection criteria
We looked for randomised controlled trials (RCTs), reported as full-text, those published as abstract only, and unpublished data; we
excluded cross-over trials.
We looked for studies where adults (aged 18 years or older) or children of school age (aged 5 years or older) with asthma were randomised
to receive: (a) any patient-/parent-initiated OCS or (b) placebo, normal care, alternative active treatment, or an identical personalised
asthma action plan without the patient- or parent-initiated OCS component.
Data collection and analysis
Two review authors independently screened the search results to identify any studies that met the prespecified inclusion criteria.
The prespecified primary outcomes were hospital admissions for asthma, asthma symptoms at follow-up and serious adverse events.
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Main results
Despite comprehensive searches of electronic databases and clinical trial registries, we did not identify any studies meeting the inclusion
criteria for this review. Five potentially relevant studies were excluded for two reasons: the intervention did not meet the inclusion
criteria for this review (three studies) and studies had a cross-over design (two studies). Two of the excluded studies asked the relevant
clinical question. However, these studies were excluded due to their cross-over design, as per the protocol. We contacted the authors of
the cross-over trials who were unable to provide data for the first treatment period (i.e. prior to cross-over).
Authors’ conclusions
There is currently no evidence from randomised trials (non-cross-over design) to inform the use of patient- or parent-initiated oral
corticosteroids in people with asthma.
P L A I N L A N G U A G E S U M M A R Y
Oral corticosteroid treatment started by patients or parents during a severe asthma attack
Background
Asthma is a long-term inflammatory disease of the airways affecting around 334 million people worldwide. During severe asthma
attacks, people may need to visit a medical centre or hospital emergency department for treatment with corticosteroids, which may
be given directly into a vein or by mouth. Some people with asthma are provided with oral steroids that they can take themselves
(patient-initiated) or give to their child (parent-initiated) in the event of a severe asthma attack. This approach to treatment is becoming
increasingly common.
Review question
We looked for studies comparing a) patient- or parent-initiated oral steroids with b) no patient- or parent-oral steroids (e.g. patient
attends a medical centre or emergency department for further treatment by a doctor or nurse). The studies had to include either adults
aged 18 years or older, or children of school age aged 5 years or older. Two review authors screened the search results independently of
each other. The initial search was performed in May 2016.
Results
We screened 61 studies in total but we found no studies matching the above criteria. Five studies were excluded because the design of
the studies was not allowed according to our review protocol. Two of these studies asked the correct clinical question but these studies
were excluded because they used a type of trial design that was not allowed according to our review protocol.
Conclusions
There is currently a lack of evidence whether the use of patient- or parent-initiated oral steroids is safe or has a beneficial treatment
effect in patients with asthma. This is a concern because this approach to treatment is becoming more common.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Patient- initiated steroids compared with placebo/ normal care/ alternative active treatment for asthma
Patient or population: adults aged 18 years or older with asthma
Settings: outpat ient
Intervention: pat ient-init iated oral cort icosteroids
Comparison: placebo/ normal care/ alternat ive act ive treatment
Outcomes Number of participants
(studies)
Comments
Hospital admissions for asthma 0 (0 studies) No studies met the inclusion criteria for this
review
Asthma control (validated scales) 0 (0 studies)
Serious adverse events (all cause) 0 (0 studies)
Unscheduled visit to a healthcare
provider
0 (0 studies)
Health- related quality of life (validated
scales)
0 (0 studies)
Days lost of study/ work 0 (0 studies)
Adverse events (all cause) 0 (0 studies)
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and
may change the est imate
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is
likely to change the est imate
Very low quality: We are very uncertain about the est imate
B A C K G R O U N D
Description of the condition
Asthma is a chronic condition of the airways affecting an estimated
334 million people worldwide (Global Asthma Report 2014). Di-
rect treatment costs and indirect costs associated with lost produc-
tivity are substantial and are among the highest for non-commu-
nicable diseases (Global Asthma Report 2014). Asthma triggers
may be allergic or non-allergic, resulting in airway inflammation
(including an eosinophilic and/or neutrophilic component), hy-
per-responsiveness and airflowobstruction.During a worsening of
asthma symptoms (i.e. an exacerbation), which include tightness
of the chest, wheeze and breathlessness, patients will typically ex-
hibit an acute narrowing of the airway and reduced lung function
(BTS/SIGN 2016). Impairment of lung function can be reversed
with treatment and may return to normal. From a patient perspec-
tive, the goals of asthma treatment are to prevent exacerbations,
achieve control of daytime and nocturnal symptoms, and permit
normal exercise and functional capacity (GINA 2016). Treatment
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of asthma should be guided by a personalised asthma action plan
(GINA 2016), and includes the avoidance of potential triggers,
the use of inhaled corticosteroids (ICS) or leukotriene receptor
antagonists or both to reduce airway inflammation, and the use of
inhaled long-acting beta2-agonists (LABA), short-acting beta2-ag-
onists (SABA) and anti-cholinergic bronchodilators (i.e. long-act-
ing muscarinic antagonists (LAMAs) to relieve airflow limitation
(NICE 2007; NICE 2013; BTS/SIGN 2016; GINA 2016). Dur-
ing severe exacerbations, patients may need to attend a medical
centre or hospital emergency department for treatment with sys-
temic corticosteroids, which can be administered intravenously or
orally (BTS/SIGN 2016; GINA 2016). Some people with asthma
are prescribed oral corticosteroids (OCS) for self-administration
(i.e. patient-initiated) or to administer to their child with asthma
(i.e. parent-initiated), in the event of an exacerbation (Vuillermin
2007).
Description of the intervention
Prophylactic treatment with corticosteroids is commonly used in
patients with asthma to reduce and control airway inflammation
(BTS/SIGN 2016; GINA 2016), thus serving to improve asthma
control and reduce future risks. ICS are used in preference to sys-
temic corticosteroids because the inhaled dose is delivered directly
to the respiratory tract (i.e. drug target), lowering the propensity
for systemic side effects. Adverse effects associated with the long-
term use of systemic steroids include: effects on bone density (e.g.
osteoporosis and increased risk of femur neck fractures), growth
retardation in children, a tendency to hyperglycaemia, and sup-
pression of the response to infection or injury (Rang 2015). Recur-
rent short courses of prednisolone may also be associated with ad-
verse events, in particular, with a reduction of bonemineral accrual
as reported among participants in the Childhood Asthma Man-
agement Program (CAMP) trial (CAMP Research Group 2000;
Kelly 2008). However, evidence supports the short-term use of
systemic corticosteroids during acute asthma exacerbations (Rowe
2007; Fernandes 2014). Patients remain particularly prone to re-
peat exacerbations in the period immediately after an asthma ex-
acerbation and the use of systemic steroids can reduce the risk of
a relapse and the need for reliever inhalers, without major adverse
effects (Rowe 2007). Prescription of a ’rescue pack’ (containing a
course of OCS) to a patient or their career permits self-admin-
istered treatment in the event of an exacerbation, as guided by a
patient’s personalised asthma action plan (BTS/SIGN 2016).
How the intervention might work
Patient-initiated OCS may feature as part of a written asthma ac-
tion plan (GINA 2016), which should state when and how to initi-
ate treatment with OCS, and when to access medical care if symp-
toms fail to respond to treatment. Compared with OCS admin-
istered by an emergency department physician, patient- or par-
ent-initiated treatment permits early administration of systemic
corticosteroids following the onset of an acute exacerbation. The
benefits of OCS have been demonstrated within three hours of
administration, and delayed dosing of OCS is less effective at re-
solving acute asthma (Streetman 2002). Indeed, there is some ev-
idence from studies in children that early administration of sys-
temic steroids during an exacerbation can reduce asthma symp-
toms and the number of days of missed school, compared with
physician-initiated steroids (Vuillermin 2010). Furthermore, re-
current severe exacerbations are associated with accelerated lung
function decline, suggesting that aggressive treatment of intermit-
tent airway inflammation may be important to prevent airway re-
modelling (Bai 2007).
Why it is important to do this review
The use of patient-initiated oral steroids is common practice in
chronic obstructive pulmonary disease (COPD) (DoH 2010) and
the appropriate use of rescue packs is currently included in a Na-
tional Institute for Health and Care Excellence (NICE) quality
statement for managing COPD (NICE 2010). In line with their
use in COPD, the use of patient- and parent-initiated OCS for
asthma appears to be increasingly common in clinical practice
(Vuillermin 2007; BTS/SIGN 2016). For example, in an Aus-
tralian survey of 252 doctors involved in the care of children with
asthma, 85% of doctors reported recommending parent-initiated
OCS to parents of children with asthma (Vuillermin 2007). Addi-
tionally, British Thoracic Society/Scottish Intercollegiate Guide-
linesNetwork (BTS/SIGN) guidelines on personalised action plan
content recommend coverage on starting oral steroids, “which
may include provision of an emergency course of steroid tablets”
(BTS/SIGN 2016). However, to date there is limited evidence for
the use of patient- or parent-initiated OCS for treating asthma ex-
acerbations (NACA 2015). An earlier Cochrane review evaluated
the evidence around parent-initiated oral corticosteroid therapy
for intermittent wheezing illnesses in children (Vuillermin 2006).
We will not consider pre-school wheeze in the present review.
It is important to consider the potential benefits of earlier treat-
ment with OCS against potential harms, which include the safety
issues around delaying access to medical care when OCS are taken
at home. Furthermore, the provision of rescue packs to patients
with asthma or to their carers will likely increase overall admin-
istration of oral corticosteroids; this has implications for the in-
cidence of steroid-associated side-effects, particularly in children.
Taken together, this information highlights the importance of syn-
thesising the evidence to establish whether this intervention is safe
and effective in people with asthma.
O B J E C T I V E S
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To evaluate the effectiveness and safety of patient- or parent-ini-
tiated oral steroids for adults and children with asthma exacerba-
tions.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We planned to include randomised controlled trials (RCTs), re-
ported as full-text, those published as abstract only, and unpub-
lished data.We excluded cross-over trials because the effects of cor-
ticosteroids can persist for a number of weeks ormonths (Haahtela
1994) and studies did not employ a sufficient washout period be-
tween treatment periods to eliminate cross-over effects.
Types of participants
We planned to include adults (aged ≥ 18 years) and children of
school age or older (i.e. aged≥ 5 years) with a diagnosis of asthma.
Adults and children were to be considered in separate compar-
isons. Preschool wheeze was not considered by this review and as
such we excluded studies of preschool children. The diagnosis of
asthma was required to be determined by a clinician according to
validated national or international guidelines. We excluded par-
ticipants with any respiratory comorbidities (e.g. bronchiectasis,
chronic obstructive pulmonary disease). If a study contained both
adults and children, we contacted the study authors to check if
disaggregated data were available; if we were unable to source these
data we used the average age (≥ 18 years) of study participants
to determine suitability for inclusion. If the average age of study
participants was less than 18 years, we planned to perform a sensi-
tivity analysis to examine the effect of including or excluding these
studies. Finally, if a study included children of both school and
preschool age, we excluded the study if the average age was less
than five years old.
Types of interventions
We planned to include studies comparing any patient- or parent-
initiated oral corticosteroid (OCS), with either placebo, normal
care, an alternative active treatment plan (e.g. doubling the dose of
inhaled steroids) or an identical personalised asthma exacerbation
management plan without patient- or parent-initiated OCS.OCS
(any dose or duration) could be combined with other measures
for the management of an exacerbation (e.g. personalised asthma
action plan, increased use of reliever inhaler) provided that the
measure was not part of the randomised treatment. We planned
to perform separate comparisons for each type of comparator (e.g.
patient-initiated steroids versus placebo; patient-initiated steroids
versus normal care, etc); separate comparisons would also be per-
formed for adults and children. We defined normal care as any
measure that the patient would usually take to manage an exacer-
bation (e.g. increase reliever inhaler use, seek medical advice, etc).
We also planned to include studies where the comparator group
comprised a combination of the above (e.g. personalised asthma
action plan plus placebo).
Types of outcome measures
Primary outcomes
1. Hospital admissions for asthma.
2. Asthma symptoms at follow-up (measured on a validated
scale (e.g. Asthma Control Questionnaire (ACQ))).
3. Serious adverse events.
We selected the primary outcomes to represent an important mea-
sure of resource use, a patient-reported outcome, and safety.
Secondary outcomes
1. Unscheduled visit to a healthcare provider (e.g. accident
and emergency, general practitioner).
2. New exacerbation in follow-up period (asthma control).
3. Health-related quality of life (using a validated scale).
4. Reliever medication use.
5. Days of school (children) or study/work (adults) lost.
6. Time to full resolution of symptoms.
7. Adverse events.
Reporting one or more of the outcomes listed here in the study
was not an inclusion criterion for the review. If a study used more
than one scale to report the same outcome, or if different scales
were used across studies, we planned to analyse the different scales
together using the standardised mean difference.
Search methods for identification of studies
Electronic searches
We identified trials from the Cochrane Airways Group’s Spe-
cialised Register (CAGR) (searched 18May 2016), which is main-
tained by the Information Specialist for the Group. The Regis-
ter contains trial reports identified through systematic searches
of bibliographic databases including the Cochrane Central Reg-
ister of Controlled Trials (CENTRAL; 2016, Issue 4) in the
Cochrane Library; MEDLINE Ovid; Embase Ovid; CINAHL
EBSCO (Cumulative Index to Nursing and Allied Health Liter-
ature; AMED Ovid (Allied and Complementary Medicine; and
PsycINFO Ovid; and handsearching of respiratory journals and
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meeting abstracts (see Appendix 1 for further details).We searched
all records in the CAGR using the search strategy in Appendix 2.
We also conducted a search of theUSNational Institutes ofHealth
Ongoing Trials Register ClinicalTrials.gov (www.clinicaltrials.gov;
searched 24 August 2016) and the World Health Organiza-
tion International Clinical Trials Registry Platform (apps.who.int/
trialsearch; searched 24 August 2016).
When searching all databases we imposed no restriction on lan-
guage of publication.
Searching other resources
We checked the reference lists of all primary studies and review
articles for additional references. We searched relevant manufac-
turers’ websites for trial information.
We planned to search for errata or retractions from included stud-
ies published in full-text on PubMed (www.ncbi.nlm.nih.gov/
pubmed) and to report the date this was done.
Data collection and analysis
Selection of studies
Two review authors (MBG, MG) independently screened titles
and abstracts of all the potentially-relevant studies that we identi-
fied as a result of the search and coded them as ’retrieve’ (eligible or
potentially eligible/unclear) or ’do not retrieve’. We retrieved the
full-text study reports/publication and two review authors (MBG,
MG) independently screened the full-text articles to confirm stud-
ies for inclusion, or to identify and record reasons for exclusion of
the ineligible studies. We resolved any disagreement through dis-
cussion or, if required, we consulted a third review author (MM).
We identified and excluded duplicates and collated multiple re-
ports of the same study, so that each study rather than each report
is the unit of interest in the review. We recorded the selection pro-
cess in sufficient detail to complete a PRISMA flow diagram and
’Characteristics of excluded studies’ table (Moher 2009).
Data extraction and management
We planned to use a data collection form for study characteristics
and outcome data, which would be piloted on at least one study
in the review. Two review authors (MBG, DE) planned to extract
study characteristics from included studies. We planned to extract
the following study characteristics.
1. Methods: study design, total duration of study, details of
any ’run in’ period, number of study centres and location, study
setting, withdrawals, and date of study.
2. Participants: number, mean age, age range, gender, severity
of condition, diagnostic criteria, baseline lung function, smoking
history, inclusion and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
Two review authors (MBG, DE) planned to independently extract
outcome data from the included studies.We planned to note in the
’Characteristics of included studies’ table if outcome data were not
reported in a usable way. We planned to resolve disagreements by
consensus or by involving a third review author (MM).One review
author (DE) was responsible for transferring data into the Review
Manager (RevMan 2014) file. We planned to double-check that
data were entered correctly by comparing the data presented in the
systematic review with the study reports. A second review author
(DE) was responsible for spot-checking study characteristics for
accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (MBG, DE) planned to independently as-
sess risk of bias for each study using the criteria outlined in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). We planned to resolve any disagreements by discussion or
by involving another review author (MM). We planned to assess
the risk of bias according to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We planned to grade each potential source of bias as high, low or
unclear risk, and provide a quote from the study report together
with a justification for our judgement in the ’Risk of bias’ table.
We planned to summarise the ’Risk of bias’ judgements across
different studies for each of the domains listed, and to consider
blinding separately for different key outcomes where necessary
(e.g. for unblinded outcome assessment, risk of bias for all-cause
mortality may be very different than for a patient-reported pain
scale). Where information on risk of bias relates to unpublished
data or correspondence with a trialist, we planned to note this in
the ’Risk of bias’ table.
When considering treatment effects, we would take into account
the risk of bias for the studies that contribute to that outcome.
Assesment of bias in conducting the systematic
review
We conducted the review according to the published protocol
(Ganaie 2016) and reported any deviations from it in the ’Dif-
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ferences between protocol and review’ section of the systematic
review.
Measures of treatment effect
We planned to analyse dichotomous data as odds ratios and con-
tinuous data as mean difference or standardised mean difference.
We planned to enter data presented as a scale with a consistent
direction of effect.
We planned to undertakemeta-analyses only where this wasmean-
ingful (i.e. if the treatments, participants and the underlying clin-
ical question were similar enough for pooling to make sense).
We planned to narratively describe skewed data reported as medi-
ans and interquartile ranges.
Where multiple trial arms were reported in a single trial, we
planned to include only the relevant arms. If two comparisons (e.g.
drug A versus placebo and drug B versus placebo) were combined
in the same meta-analysis, we planned to halve the control group
to avoid double-counting.
Unit of analysis issues
For dichotomous outcomes, we planned to report participants,
rather than events, as the unit of analysis. For example, for the
secondary outcome ’unscheduled visit to a healthcare provider’
we would record the number of participants with an unscheduled
visit, rather than the number of unscheduled visits per participant.
Dealing with missing data
We planned to contact investigators or study sponsors in order
to verify key study characteristics and obtain missing numerical
outcome data where possible (e.g. when a study was identified as
abstract only). Where this was not possible, and the missing data
were thought to introduce serious bias, we planned to explore the
impact of including such studies in the overall assessment of results
by conducting a sensitivity analysis.
Assessment of heterogeneity
We planned to use the I2 statistic to measure heterogeneity among
the studies in each analysis. If we identified substantial heterogene-
ity we would report it and explore possible causes by prespecified
subgroup analysis.
Assessment of reporting biases
If we were able to pool more than 10 studies, we planned to create
and examine a funnel plot to explore possible small study and
publication biases.
Data synthesis
We planned to use a random-effects model and perform a sensi-
tivity analysis with a fixed-effect model.
’Summary of findings’ table
We created a ’Summary of findings’ table for each comparison
using the following outcomes: hospital admissions for asthma;
asthma symptoms at follow-up; serious adverse events; unsched-
uled visit to a healthcare provider; asthma control at follow-up;
days of school or study/work lost; and adverse events. We planned
to use the five GRADE considerations (study limitations, consis-
tency of effect, imprecision, indirectness and publication bias) to
assess the quality of a body of evidence as it relates to the studies
which contribute data to the meta-analyses for the prespecified
outcomes (Guyatt 2011). We planned to use methods and rec-
ommendations described in Section 8.5 and Chapter 12 of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011) using GRADEpro GDT software (GRADEpro GDT). We
planned to justify all decisions to downgrade or upgrade the qual-
ity of studies using footnotes and to make comments to aid the
reader’s understanding of the review where necessary.
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses.
1. Baseline asthma severity (stratified by background
medication).
We planned to use the following outcomes in subgroup analyses.
1. Hospital admissions for asthma.
2. Asthma symptoms at follow-up.
3. Serious adverse events.
We planned to use the formal test for subgroup interactions in
Review Manager (RevMan 2014).
Sensitivity analysis
If necessary, we planned to carry out the following sensitivity anal-
yses to explore the effect of including/excluding:
1. studies that included both adults and children/adolescents,
where the average age of participants was < 18 years;
2. unpublished data (i.e. no peer-reviewed full-text paper
available);
3. studies at high risk of performance or detection bias;
4. studies at high risk of any other bias;
5. studies with missing data.
R E S U L T S
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Description of studies
Results of the search
A search of the Cochrane Airways’ Specialised Register (CASR)
returned 55 references and the search of the US National Insti-
tutes of Health Ongoing Trials Register ClinicalTrials.gov and the
World Health Organization International Clinical Trials Registry
Platform yielded a further 7 records. Two review authors screened
the 62 references/records using Covidence (Covidence 2016) and
54 records were discarded. We selected eight references (five stud-
ies) as potential candidates for inclusion in this review and sourced
the corresponding full-text articles. Two review authors screened
the full-text articles independently and all five studies were ex-
cluded with reasons. The PRISMA flow diagram is presented in
Figure 1.
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Figure 1. Study flow diagram.
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Included studies
We included no studies.
Excluded studies
We excluded five studies with reasons (see Characteristics of
excluded studies table). Three studies were excluded because the
intervention did not meet the criteria for inclusion in this review
(oral corticosteroids (OCS) must be part of the randomised treat-
ment and could be combined with other measures for the man-
agement of an exacerbation such as a personalised asthma action
plan, provided that the co-intervention was not part of the ran-
domised treatment). Specifically, the OCS were not part of the
randomised treatment in the study by Boushey 2005. Participants
in the study reported by Milenovi 2007 could initiate oral cor-
ticosteroids as per a personalised asthma action plan (i.e. co-in-
tervention), which was part of the randomised treatment and was
not available to participants in the control group. In vanDerMeer
2009, the oral corticosteroids were optional at step seven of an in-
ternet-based asthma plan (i.e. co-intervention), which was part of
the randomised treatment. Furthermore, the oral corticosteroids
were taken following contact with an asthma nurse, and the usual
care group received no plan. Two studies were excluded because
of their cross-over design (Grant 1995; Vuillermin 2010); we con-
tacted the authors of the respective studies, who were unable to
provide data for the first treatment period (i.e. prior to cross-over).
Risk of bias in included studies
Not applicable.
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings: patient-initiated steroids; Summary of findings 2
Summary of findings: parent-initiated steroids
Not applicable.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Parent- initiated steroids compared with placebo/ normal care/ alternative active treatment for asthma
Patient or population: children aged 5 years or older with asthma
Settings: outpat ient
Intervention: parent-init iated oral cort icosteroids
Comparison: placebo/ normal care/ alternat ive act ive treatment
Outcomes Number of participants
(studies)
Comments
Hospital admissions for asthma 0 (0 studies) No studies met the inclusion criteria for this
review
Asthma control (validated scales) 0 (0 studies)
Serious adverse events (all cause) 0 (0 studies)
Unscheduled visit to a healthcare
provider
0 (0 studies)
Health- related quality of life (validated
scales)
0 (0 studies)
Days off school 0 (0 studies)
Adverse events (all cause) 0 (0 studies)
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and
may change the est imate
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is
likely to change the est imate
Very low quality: We are very uncertain about the est imate
D I S C U S S I O N
Summary of main results
After screening the results of extensive searches, we identified no
relevant randomised controlled trials to include in this review.
Five potentially relevant studies were excluded based on our pre-
specified criteria. Two of the excluded studies asked the relevant
clinical question (Grant 1995; Vuillermin 2010). However, these
studies were excluded due to their cross-over design, as per the
protocol. The authors were contacted but were unable to provide
data for the first treatment period only (i.e. prior to cross-over).
Overall completeness and applicability of
evidence
We identified no relevant studies to include in this review.
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Quality of the evidence
Despite performing a comprehensive search and a duplicate (in-
dependent) screening and reviewing process, we identified no rel-
evant studies to include in this review.
Potential biases in the review process
This review process could potentially be subject to a risk of bias in
two areas: searching and drawing conclusions.However, Cochrane
Airways’ Information Specialist designed and conducted the main
electronic search and two clinicians in the author team (MG,
MBG) with expert knowledge in the area independently sifted and
reviewed the search results. Consistent with Cochrane methodol-
ogy, we excluded no trials on the basis of language, publication
status, or the outcomes reported, so we are confident that we iden-
tified all potentially relevant randomised evidence. Our conclu-
sions are consistent with the lack of included studies.
Agreements and disagreements with other
studies or reviews
To our knowledge, there are no existing systematic reviews on this
topic. The two randomised controlled trials that asked the relevant
clinical question, but were excluded from the present review due
to their cross-over design, reported contrasting findings. Grant
and colleagues examined the effectiveness of a single oral dose of
prednisone administered by a parent to a child early in an asthma
attack (Grant 1995). Contrary to expectation, the authors found
that participants in the parent-initiated oral prednisone group had
significantly more asthma exacerbations resulting in outpatient
visits than when they were in the placebo group (Grant 1995).
The authors speculated that the results may be specific for a pop-
ulation of children with suboptimal use of beta-agonist therapy,
and stressed that further studies are required in different popula-
tions of asthmatic children (Grant 1995). In contrast, Vuillermin
and colleagues found that among children of school age, a short
course of parent-initiated oral prednisolone during an asthma ex-
acerbation may result in a reduction in asthma symptoms, health
resource use, and days off school (Vuillermin 2010). However, the
authors cautioned that the modest benefits of this strategy should
be balanced against potential side effects of repeated oral corticos-
teroid use (Vuillermin 2010).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
A previous Cochrane review found that a short course of corti-
costeroids following assessment for an asthma exacerbation signif-
icantly reduced the number of relapses requiring additional care,
hospitalisations and the use of short-acting beta2-agonists, with-
out an apparent increase in side effects (Rowe 2007). However,
there is currently no evidence to support the use of patient- or par-
ent-initiated oral corticosteroids (OCS) in the event of an asthma
exacerbation.
Asthma is characterized by chronic airway inflammation, that is
predominantly eosinophilic and corticosteroid-sensitive. However
long-term adherence to inhaled corticosteroids (ICS) is typically
low in clinical practice, which can lead to suboptimal asthma con-
trol and asthma exacerbations (Weinstein 2015). Hence, in any
patient-initiated OCS strategy, it is crucial to ascertain patient
compliance to ICS and optimal inhaler technique. In mild-mod-
erate asthma cases, a Single Maintenance And Reliever Therapy
(SMART) approach is an alternative option that allows for patient
autonomy in self-titration of ICS, and has been shown to improve
asthma control and reduce need for exacerbations requiring OCS,
though it did not reduce hospitalisation rates (Cates 2013). How-
ever, only a relatively small proportion of patients on SMART
are controlled and many continue to have eosinophilic inflam-
mation (Chapman 2010). In severe asthma, where up to 50% of
the patients have non-eosinophilic airway inflammation, sputum-
guided titration of treatment is shown to reduce exacerbations
(Petsky 2012). In view of these real-life issues, patient-initiated
OCSmight pose problems for misuse and abuse, if doctors do not
first ensure that their patients are adherent to ICS and that severe
asthma cases are not relegated to recurrent OCS bursts when they
might be suitable for novel biologics or bronchial thermoplasty,
depending on patient-specific disease mechanisms.
In conclusion, though guidelines recommend that written asthma
action plans consider patient-initiated OCS, to facilitate early
treatment of a significant asthma exacerbation, current evidence
is scarce.
Implications for research
A double-blind, parallel-arm, randomised controlled trial to as-
sess this question would help clinicians to judge whether it is safe
and effective for parents or patients to initiate treatment with oral
corticosteroids in the event of an asthma exacerbation. Ideally, at
least one adequately powered trial would be performed in each of
the relevant age groups (children and adolescents; adults). Addi-
tionally, future studies would includemild-moderate asthma cases,
objectively monitor patient ICS adherence rates and, if feasible,
measure blood and airway eosinophilia at baseline and during an
exacerbation.Wewould recommend that future trials on this topic
do not use a cross-over design due to concerns around the elimi-
nation of cross-over effects.
A C K N OW L E D G E M E N T S
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The Background and Methods sections of this review are based
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Elizabeth Stovold for designing the search strategy, and Rebecca
Normansell andEmmaWelsh for their contribution to the content
and methodology of the review.
Rebecca Normansell was the contact editor for this review and
commented critically on the review.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Boushey 2005 OCS was not part of the randomised treatment
Grant 1995 Cross-over design
Milenovi 2007 OCS was administered as part of asthma action plan (i.e. co-intervention), which was part of randomised
treatment
van Der Meer 2009 OCS could be optionally administered as part of asthma action plan, which was part of randomised treatment
Vuillermin 2010 Cross-over design
OCS = oral corticosteroids.
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Sources and search methods for Cochrane Airways Group’s Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL (Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
Embase (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (-Ovid?) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
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(Continued)
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify randomised controlled trials (RCTs)
1. exp “clinical trial [publication type]”/
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
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Appendix 2. Search strategy to identify relevant trials from the CAGR
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 prednis*
#6 methylprednis*
#7 dexamethasone
#8 cortisone
#9 hydrocortisone*
#10 medrol
#11 solumedrol
#12 solu-medrol
#13 betamethasone
#14 triamcinolone
#15 (oral* or systemic*) near3 (steroid* or corticosteroid* or glucocorticoid*)
#16 OCS:ti,ab
#17 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16
#18 MeSH DESCRIPTOR Patient Participation
#19 MeSH DESCRIPTOR Decision Making
#20 (patient* or parent* or caregiver* or career*) NEAR (initiat* or suggest* or instigat* or originat* or request* or propose* or
encourage* or advocate*)
#21 self-refer* or self NEXT refer*
#22 #18 or #19 or #20 or #21
#23 #4 AND #17 AND #22
#24 (#23) AND (INREGISTER)
(Note: in search line #1, MISC1 denotes the field in the record where the reference has been coded for condition, in this case, asthma)
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The review was performed as per the protocol. We substituted one of the secondary outcomes for health-related quality of life as the
outcome in question (asthma control) was already included as a primary outcome.
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